Determination of the renin inhibitor Ro 42-5892 in human plasma by automated pre-column derivatization, reversed-phase high-performance liquid chromatographic separation and electrochemical detection after post-column irradiation

Leube, Joachim; Fischer, G.

doi:10.1016/0378-4347(94)00542-d

Cited by 4 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…43 As a reference method, the authors used the HPLC method employing reversed phase chromatography on a C 18 column and post-column irradiation using a BeamBoost® followed by coulometric oxidative electrochemical detection at +550 mV vs. a H2/H 0 electrode, obtaining in this case a quanti-cation limit on the level of 0.2 ng mL À1 . Another method for remikiren determination in blood serum was proposed by Leube and Fischer, 44 and analysis was conducted using the HPLC method with pre-column derivatization of the examined substance with 2,4-dinitrouorobenzene and electrochemical detection; Ro-4661/000 compound was used as a standard. The derivatization process was performed automatically using borate buffer (0.2 M, pH 8.0) and 2,4-dinitrouorobenzene.…”

Section: Remikirenmentioning

confidence: 99%

Pharmacological and therapeutic properties of new derivatives of renin inhibitors and endothelin receptor antagonists, and the methods of their determination

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Remikirenmentioning

confidence: 99%

Pharmacological and therapeutic properties of new derivatives of renin inhibitors and endothelin receptor antagonists, and the methods of their determination

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The second method used was a specific h.p.l.c. method employing reversed phase chromatography on a C18 column and post-column irradiation using a Beam Boost® followed by coulometric oxidative electrochemical detection at +550 mV vs a H2/H' electrode [17]. The limit of quantification was 0.2 ng ml-'.…”

Section: Pharmacokinetics and -Dynamics Of Remikiren 549mentioning

confidence: 99%

Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42–5892) in hypertensive patients

Weber

Birnböck

Leube

et al. 1993

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 Three double-blind, randomized, placebo controlled, multiple oral dose studies in patients with mild to moderate hypertension were performed to study tolerability, pharmacodynamics and pharmacokinetics of remikiren. Doses of 100-800 mg remikiren or placebo were given over 8 days to altogether 144 patient volunteers. In some cases (n = 46) single i.v. doses of 100 mg were administered 4 h after the last oral dose. Plasma remikiren concentrations, plasma renin activity and immunoreactive renin concentrations were measured. Pharmacokinetic parameters were estimated using model independent techniques and the concentration-effect relationship was evaluated using population pharmacometric methods. 2 In most patients no distinct absorption and disposition phase could be identified, since plasma concentrations fluctuated widely over a period of approximately 10 h. Peak plasma concentrations (Cmax) were achieved within 0.25-2 h postdose. Mean Cmax values (on the first and last day of oral treatment) were in the magnitude of 4-6 ng ml-1 (200 mg), 23-27 ng ml-1 (300 mg), 65-83 ng ml-1 (600 mg) and 47-48 ng ml-1 (800 mg). Cmax and AUCO-t values were clearly different for different doses within single studies. Intersubject variability in pharmacokinetic parameters was much higher than intrasubject variability. No drug accumulation in plasma was apparent. 3 Inhibition of the angiotensin I production rate correlated well with plasma drug concentrations according to the Emax-model. An IC50 value of 0.5 ng ml-1 (0.8 nM)was estimated. No correlation between blood pressure changes on the last day of oral treatment and either plasma remikiren concentrations or plasma renin inhibition was found.

show abstract

Automation of sample pretreatment for liquid chromatography

Tolokán

Horvai

1998

Mikrochim Acta

View full text Add to dashboard Cite

Determination of the renin inhibitor Ro 42-5892 in human plasma by automated pre-column derivatization, reversed-phase high-performance liquid chromatographic separation and electrochemical detection after post-column irradiation

Cited by 4 publications

References 18 publications

Pharmacological and therapeutic properties of new derivatives of renin inhibitors and endothelin receptor antagonists, and the methods of their determination

Pharmacological and therapeutic properties of new derivatives of renin inhibitors and endothelin receptor antagonists, and the methods of their determination

Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42–5892) in hypertensive patients

Automation of sample pretreatment for liquid chromatography

Contact Info

Product

Resources

About